Broadly, the effect of the BH3 mimetics was similar between the healthy and BP-CML samples (Fig. 5A), although when expressed as a change from the no drug control (NDC), the combination of S63845 and A-1331852 reduced the CD34+ population in the BP-CML samples to a significantly greater degree than in the healthy samples (healthy: −28.15 ± 11.74%; BP-CML: −55.95 ± 9.48%; p = 0.0482), suggesting a specific response to these drugs in the primitive BP-CML cells. Here, CD34 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.